Jazz and Zymeworks Present P-IIb Trial (HERIZON-BTC-01) Results of Zanidatamab for HER2-Amplified Biliary Tract Cancers at ASCO 2023
Shots:
- The P-IIb trial evaluating zanidatamab (20mg/kg, IV, q2w) in 87 patients at 32 trial sites in 9 countries in North America, South America, Asia & EU
- The results showed a cORR (41.3%) with a KM estimated m-DoR (12.9mos.) with a median study follow-up time of 12.4mos. & m-PFS was 5.5mos. among 80 patients & rapid, durable responses with a manageable safety profile, CR (1%), PR (32%), SD (22%), PD (24%) & DCR (68.8%), no responses were reported in cohort 2. The results were published in The Lancet Oncology
- As the data cut off Oct 2022, ongoing responses (49%), DoR of ≥16wks. (81.8%) among 33 patients, the median time to first confirmed response was 1.8mos. along with a manageable & tolerable safety profile, 2.3% experienced AEs leading to treatment discontinuation
Ref: PRNewswire | Image: Jazz Pharmaceuticals
Related News:- Jazz Pharmaceuticals Exercised its Option to Advance Zymeworks' Zanidatamab for Cancer Patients
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
